On February 8, 2022 Patrys reported that new data from a preclinical study that demonstrated potential for using our deoxymab antibodies as targeting agents in ADCs (Press release, Patrys, FEB 8, 2022, View Source [SID1234607814]). This was a promising development, and one which opens up a range of possibilities for our platform in precision medicine.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ADCs harness the targeting attributes of antibodies to deliver drugs specifically to the sites of disease.

Our preclinical study has shown the affinity our deoxymabs have for DNA is sufficient for them to target the delivery of cancer drugs to tumours, where they can inhibit tumour growth and improve survival.